Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARIZ PRDM16 siRNA
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
ARIZ Precision Medicine-PRDM16-siRNA-Leukemia is an experimental siRNA-based therapeutic candidate developed by ARIZ Precision Medicine for the treatment of leukemia. The drug is designed to target and silence the PRDM16 (PR domain zinc finger protein 16) gene, an epigenetic regulator that is frequently overexpressed or dysregulated in leukemic cells, contributing to oncogenesis. The therapeutic utilizes ARIZ's proprietary Targeted Drug Delivery System (T-DDS), which is a nanoparticle-based platform engineered to selectively deliver the siRNA payload to cancer cells. By mediating the knockdown of PRDM16 mRNA, the drug aims to disrupt the signaling pathways that drive leukemia progression. The program is currently in the early research and development phase, having demonstrated proof-of-principle in the T-DDS platform.
- Other names
- ARIZ Precision Medicine-PRDM16-siRNA-LeukemiaPRDM16 siRNAPRDM-16 siRNAPRDM 16 siRNAARIZ Leukemia Program
02
Targets
PRDM16 (PR domain zinc finger protein 16)
Beyond the preview
Go deeper on ARIZ PRDM16 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARIZ PRDM16 siRNA.